Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study

被引：0
|
作者：
Younes, A. [1 ]
Andreadis, C. [2 ]
Assouline, S. [3 ]
Rizzieri, D. [4 ]
Wedwood, A. [1 ]
McLaughlin, P. [1 ,5 ]
Laille, E.
Li, Z. [6 ]
Martell, R. E. [6 ]
Crump, M. [7 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Sir Mortimer B Davis Jewish Hosp, Montreal, PQ, Canada
[4] Duke Univ, Med Ctr, Durham, NC 27706 USA
[5] Pharmion Corp, Phamaco & PK, Boulder, CO USA
[6] MethylGene Inc, Drug Dev, Montreal, PQ, Canada
[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：162 / 162
页数：1
相关论文
共 50 条
  • [21] Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
    Blum, Kristie A.
    Advani, Anjani
    Fernandez, Louis
    Van Der Jagt, Richard
    Brandwein, Joseph
    Kambhampati, Suman
    Kassis, Jeannine
    Davis, Melanie
    Bonfils, Claire
    Dubay, Marja
    Dumouchel, Julie
    Drouin, Michel
    Lucas, David M.
    Martell, Robert E.
    Byrd, John C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (04) : 507 - 514
  • [22] Interim results of a phase II multicenter study with the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory follicular lymphoma.
    Gui, Lin
    Cheng, Ying
    Wang, Huaqing
    Cao, Junning
    Li, Zhenling
    Zhang, Lei
    Gao, Yuhuan
    Li, Yufu
    Xu, Weijie
    Li, Xiang
    Ke, Xiaoyan
    Jing, Hongmei
    Zhang, Qingyuan
    Xi, Yaming
    Liu, Tingbo
    Wang, Zhen
    Gao, Yajie
    Pan, Qin
    Zou, Liqun
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Mocetinostat (MGCD0103) or MG0103 is an isotype-selective histone deacetylase (HDAC) inhibitor induce apoptosis and suppress tumor in glioblastoma cell lines C6 and T98G
    Khathayer, F.
    ANNALS OF ONCOLOGY, 2022, 33 (08) : S1409 - S1409
  • [24] Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS).
    Garcia-Manero, G.
    Minden, M.
    Estrov, Z.
    Verstovsek, S.
    Newsome, W. M.
    Reid, G.
    Besterman, J.
    Li, Z.
    Pearce, L.
    Martell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 337S - 337S
  • [25] Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor
    Walewski, Jan
    Paszkiewicz-Kozik, Ewa
    Borsaru, Gabriela
    Moicean, Andreea
    Warszewska, Agnieszka
    Strobel, Klaus
    Biggi, Alberto
    Hauns, Bernhard
    Mais, Anna
    Henning, Stefan W.
    Hentsch, Bernd
    BLOOD, 2010, 116 (21) : 1159 - 1159
  • [26] ABEXINOSTAT (S78454) A HISTONE DEACETYLASE INHIBITOR, IN PATIENTS WITH REFRACTORY OR RELAPSED HODGKIN'S LYMPHOMA, NON-HODGKIN LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA: PRELIMINARY PHASE II RESULTS
    Broussais-Guillaumot, F.
    Morschhauser, F.
    Terriou, L.
    Kim, W. S.
    Lim, S. T.
    Egyed, M.
    Coiffier, B.
    Bachy, E.
    Dyer, M. J.
    Illes, A.
    Rosta, A.
    Lemieux, B.
    Wu, K. L.
    Yoon, S. S.
    Kim, S.
    Gasztonyi, Z.
    Jakucs, J.
    Offner, F.
    Van den Neste, E.
    Ysebaert, L.
    Wendtner, C. M.
    Kloos, I.
    Sarry, A. L.
    Malasse, S.
    Ribrag, V.
    HAEMATOLOGICA, 2014, 99 : 141 - 142
  • [27] Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin lymphoma
    Wiernik, P. H.
    Lossos, I. S.
    Tuscano, J.
    Justice, G.
    Vose, J. M.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J.
    Habermann, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma
    Witzig, Thomas E.
    Vose, Julie M.
    Moore, Timothy D.
    Reeder, Craig B.
    Cole, Craig E.
    Justice, Glen
    Kaplan, Henry P.
    Voralia, Michael
    Pietronigro, Dennis
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Zeldis, Jerome B.
    Wiernik, Peter H.
    BLOOD, 2007, 110 (11) : 754A - 755A
  • [29] Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
    Witzig, T. E.
    Vose, J.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J.
    Wiernik, P. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] INITIAL RESULTS FROM THE SAPHIRE STUDY: A PHASE II TRIAL WITH THE NOVEL ORAL HISTONE DEACETYLASE (HDAC) INHIBITOR RESMINOSTAT IN RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA PATIENTS
    Walewski, J.
    Paszkiewicz-Kozik, E.
    Borsaru, G.
    Moicean, A.
    Warszewska, A.
    Strobel, K.
    Biggi, A.
    Hauns, B.
    Mais, A.
    Henning, S.
    Hentsch, B.
    HAEMATOLOGICA, 2010, 95 : S27 - S27
12345